Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting
Bin Xue, Yi Liu, Aibin Liang, Wenjun Zhang
The field of chimeric antigen receptor (CAR)-T cell therapy is undergoing a paradigm shift from complex ex vivo manufacturing to direct in vivo generation of CAR-T cells. This innovative approach leverages non-viral delivery platforms to reprogram a patient's own immune cells in …
cn (code pays fourni par la source)